LH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Labcorp Holdings Inc (LH) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive news catalysts, and bullish technical indicators support this decision. Despite hedge fund selling, the long-term growth potential and analyst optimism outweigh the negatives.
The MACD histogram is positive at 0.245, indicating bullish momentum. The RSI is neutral at 39.039, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support is at 260.064, and resistance is at 276.803. The stock is trading near support, which could present a good entry point.
Labcorp's nationwide availability of Agilent Technologies' PD-L1 IHC 22C3 diagnostic, which supports FDA-approved KEYTRUDA treatments for ovarian cancer, highlights its leadership in healthcare innovation. Additionally, its role in supporting over 85% of FDA-approved drugs in 2025 reinforces its industry dominance.
Hedge funds have significantly increased their selling activity, which could indicate short-term bearish sentiment. However, insider trading remains neutral, and no significant political trades were reported.
Labcorp's Q3 2025 financials show strong growth: revenue increased by 8.58% YoY to $3.56 billion, net income surged by 54.22% YoY to $261.1 million, and EPS rose by 55.22% YoY to 3.12. Gross margin also improved to 26.82%, up 4.68% YoY.
Analysts are optimistic, with multiple firms raising price targets to $300 or higher. Evercore ISI, JPMorgan, and Baird maintain Outperform or Overweight ratings, citing Labcorp's strong financials, discounted valuation compared to peers, and its position as a safe haven in healthcare services.
